JP2014098050A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014098050A5 JP2014098050A5 JP2014040227A JP2014040227A JP2014098050A5 JP 2014098050 A5 JP2014098050 A5 JP 2014098050A5 JP 2014040227 A JP2014040227 A JP 2014040227A JP 2014040227 A JP2014040227 A JP 2014040227A JP 2014098050 A5 JP2014098050 A5 JP 2014098050A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- cancer
- daily dose
- effective amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 45
- 206010028980 Neoplasm Diseases 0.000 claims 11
- 201000011510 cancer Diseases 0.000 claims 11
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 6
- 239000002202 Polyethylene glycol Substances 0.000 claims 6
- 239000008280 blood Substances 0.000 claims 6
- 210000004369 blood Anatomy 0.000 claims 6
- 229940079593 drug Drugs 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 6
- 229940074046 glyceryl laurate Drugs 0.000 claims 6
- 229920001223 polyethylene glycol Polymers 0.000 claims 6
- ARIWANIATODDMH-UHFFFAOYSA-N rac-1-monolauroylglycerol Chemical compound CCCCCCCCCCCC(=O)OCC(O)CO ARIWANIATODDMH-UHFFFAOYSA-N 0.000 claims 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims 5
- 238000005481 NMR spectroscopy Methods 0.000 claims 5
- 239000000654 additive Substances 0.000 claims 5
- -1 glycerol ester Chemical class 0.000 claims 4
- 238000004128 high performance liquid chromatography Methods 0.000 claims 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims 3
- 229920001214 Polysorbate 60 Polymers 0.000 claims 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims 3
- 230000000996 additive effect Effects 0.000 claims 3
- 239000003963 antioxidant agent Substances 0.000 claims 3
- 235000006708 antioxidants Nutrition 0.000 claims 3
- 239000013078 crystal Substances 0.000 claims 3
- 239000012535 impurity Substances 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims 3
- 229920000136 polysorbate Polymers 0.000 claims 3
- 239000004094 surface-active agent Substances 0.000 claims 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims 2
- 206010052360 Colorectal adenocarcinoma Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 230000003078 antioxidant effect Effects 0.000 claims 2
- 239000001913 cellulose Substances 0.000 claims 2
- 229920002678 cellulose Polymers 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 235000019439 ethyl acetate Nutrition 0.000 claims 2
- 150000002632 lipids Chemical class 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- DPHUWDIXHNQOSY-UHFFFAOYSA-N napabucasin Chemical compound O=C1C2=CC=CC=C2C(=O)C2=C1OC(C(=O)C)=C2 DPHUWDIXHNQOSY-UHFFFAOYSA-N 0.000 claims 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 2
- 229920000053 polysorbate 80 Polymers 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 150000004671 saturated fatty acids Chemical class 0.000 claims 2
- 201000003076 Angiosarcoma Diseases 0.000 claims 1
- 208000001258 Hemangiosarcoma Diseases 0.000 claims 1
- 229920001213 Polysorbate 20 Polymers 0.000 claims 1
- 206010038111 Recurrent cancer Diseases 0.000 claims 1
- 206010070308 Refractory cancer Diseases 0.000 claims 1
- 102000004495 STAT3 Transcription Factor Human genes 0.000 claims 1
- 108010017324 STAT3 Transcription Factor Proteins 0.000 claims 1
- 229930182558 Sterol Natural products 0.000 claims 1
- 229930003427 Vitamin E Natural products 0.000 claims 1
- 235000014113 dietary fatty acids Nutrition 0.000 claims 1
- 239000000194 fatty acid Substances 0.000 claims 1
- 229930195729 fatty acid Natural products 0.000 claims 1
- 150000004665 fatty acids Chemical class 0.000 claims 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims 1
- 201000006585 gastric adenocarcinoma Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 208000037819 metastatic cancer Diseases 0.000 claims 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims 1
- 230000002018 overexpression Effects 0.000 claims 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims 1
- 208000016691 refractory malignant neoplasm Diseases 0.000 claims 1
- 239000013557 residual solvent Substances 0.000 claims 1
- 150000003432 sterols Chemical class 0.000 claims 1
- 235000003702 sterols Nutrition 0.000 claims 1
- 230000004083 survival effect Effects 0.000 claims 1
- 235000019165 vitamin E Nutrition 0.000 claims 1
- 229940046009 vitamin E Drugs 0.000 claims 1
- 239000011709 vitamin E Substances 0.000 claims 1
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31589010P | 2010-03-19 | 2010-03-19 | |
| US31588610P | 2010-03-19 | 2010-03-19 | |
| US61/315,890 | 2010-03-19 | ||
| US61/315,886 | 2010-03-19 | ||
| US32581410P | 2010-04-19 | 2010-04-19 | |
| US61/325,814 | 2010-04-19 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013500246A Division JP5602935B2 (ja) | 2010-03-19 | 2011-03-21 | がん幹細胞を標的とするための新規の化合物および組成物 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016194176A Division JP2016222723A (ja) | 2010-03-19 | 2016-09-30 | がん幹細胞を標的とするための新規の化合物および組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014098050A JP2014098050A (ja) | 2014-05-29 |
| JP2014098050A5 true JP2014098050A5 (enExample) | 2014-12-11 |
Family
ID=50940329
Family Applications (11)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014040227A Withdrawn JP2014098050A (ja) | 2010-03-19 | 2014-03-03 | がん幹細胞を標的とするための新規の化合物および組成物 |
| JP2014040226A Withdrawn JP2014098049A (ja) | 2010-03-19 | 2014-03-03 | がん幹細胞を標的とするための新規の化合物および組成物 |
| JP2014040225A Expired - Fee Related JP5993390B2 (ja) | 2010-03-19 | 2014-03-03 | がん幹細胞を標的とするための新規の化合物および組成物 |
| JP2015035285A Pending JP2015098489A (ja) | 2010-03-19 | 2015-02-25 | がん幹細胞を標的とするための新規の化合物および組成物 |
| JP2015179115A Expired - Fee Related JP6246169B2 (ja) | 2010-03-19 | 2015-09-11 | がん幹細胞を標的とするための新規の方法 |
| JP2016194176A Withdrawn JP2016222723A (ja) | 2010-03-19 | 2016-09-30 | がん幹細胞を標的とするための新規の化合物および組成物 |
| JP2017199380A Withdrawn JP2018002744A (ja) | 2010-03-19 | 2017-10-13 | がん幹細胞を標的とするための新規の方法 |
| JP2018081329A Withdrawn JP2018115209A (ja) | 2010-03-19 | 2018-04-20 | がん幹細胞を標的とするための新規の化合物および組成物 |
| JP2020014705A Withdrawn JP2020063308A (ja) | 2010-03-19 | 2020-01-31 | がん幹細胞を標的とするための新規の化合物および組成物 |
| JP2020082479A Pending JP2020114888A (ja) | 2010-03-19 | 2020-05-08 | がん幹細胞を標的とするための新規の方法 |
| JP2021197732A Pending JP2022020002A (ja) | 2010-03-19 | 2021-12-06 | がん幹細胞を標的とするための新規の化合物および組成物 |
Family Applications After (10)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014040226A Withdrawn JP2014098049A (ja) | 2010-03-19 | 2014-03-03 | がん幹細胞を標的とするための新規の化合物および組成物 |
| JP2014040225A Expired - Fee Related JP5993390B2 (ja) | 2010-03-19 | 2014-03-03 | がん幹細胞を標的とするための新規の化合物および組成物 |
| JP2015035285A Pending JP2015098489A (ja) | 2010-03-19 | 2015-02-25 | がん幹細胞を標的とするための新規の化合物および組成物 |
| JP2015179115A Expired - Fee Related JP6246169B2 (ja) | 2010-03-19 | 2015-09-11 | がん幹細胞を標的とするための新規の方法 |
| JP2016194176A Withdrawn JP2016222723A (ja) | 2010-03-19 | 2016-09-30 | がん幹細胞を標的とするための新規の化合物および組成物 |
| JP2017199380A Withdrawn JP2018002744A (ja) | 2010-03-19 | 2017-10-13 | がん幹細胞を標的とするための新規の方法 |
| JP2018081329A Withdrawn JP2018115209A (ja) | 2010-03-19 | 2018-04-20 | がん幹細胞を標的とするための新規の化合物および組成物 |
| JP2020014705A Withdrawn JP2020063308A (ja) | 2010-03-19 | 2020-01-31 | がん幹細胞を標的とするための新規の化合物および組成物 |
| JP2020082479A Pending JP2020114888A (ja) | 2010-03-19 | 2020-05-08 | がん幹細胞を標的とするための新規の方法 |
| JP2021197732A Pending JP2022020002A (ja) | 2010-03-19 | 2021-12-06 | がん幹細胞を標的とするための新規の化合物および組成物 |
Country Status (11)
| Country | Link |
|---|---|
| EP (2) | EP3108750B1 (enExample) |
| JP (11) | JP2014098050A (enExample) |
| CN (3) | CN106860443A (enExample) |
| CA (3) | CA2993363A1 (enExample) |
| DK (1) | DK3108750T3 (enExample) |
| ES (1) | ES2689928T3 (enExample) |
| HU (1) | HUE066482T2 (enExample) |
| NZ (2) | NZ712826A (enExample) |
| PT (1) | PT2547205T (enExample) |
| RU (2) | RU2657750C1 (enExample) |
| SG (3) | SG10201502079VA (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2200431T1 (sl) | 2007-09-10 | 2016-10-28 | Boston Biomedical, Inc. | Sestave in metode za zdravljenje raka |
| CN106860443A (zh) * | 2010-03-19 | 2017-06-20 | 北京强新生物科技有限公司 | 靶向癌症干细胞的新的化合物和组合物 |
| AU2011227023B2 (en) * | 2010-03-19 | 2015-05-28 | Boston Biomedical, Inc. | Novel methods for targeting cancer stem cells |
| US20160030384A1 (en) | 2013-04-09 | 2016-02-04 | Boston Biomedical, Inc. | 2-acetylnaphtho[2,3-b]furan -4,9-dione for use on treating cancer |
| JP2018521979A (ja) * | 2015-06-03 | 2018-08-09 | ボストン バイオメディカル， インコーポレイテッド | 癌の治療に使用するための癌幹細胞性阻害剤および免疫療法剤を含む組成物 |
| GB201515391D0 (en) * | 2015-08-28 | 2015-10-14 | Amazentis Sa | Compositions |
| GB201515387D0 (en) * | 2015-08-28 | 2015-10-14 | Amazentis Sa | Compositions |
| JP6751658B2 (ja) | 2016-11-15 | 2020-09-09 | クラリオン株式会社 | 音声認識装置、音声認識システム |
| CA3045306A1 (en) | 2016-11-29 | 2018-06-07 | Boston Biomedical, Inc. | Naphthofuran derivatives, preparation, and methods of use thereof |
| JP2020520923A (ja) | 2017-05-17 | 2020-07-16 | ボストン バイオメディカル， インコーポレイテッド | がんを処置するための方法 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS61205257A (ja) * | 1985-03-08 | 1986-09-11 | Ishihara Sangyo Kaisha Ltd | ベンゾイルウレア系化合物、その製法及びそれを含有する抗ガン剤 |
| EP0945131A1 (de) * | 1998-03-27 | 1999-09-29 | Boehringer Ingelheim Pharma KG | Perorale Wirkstoff-Suspension |
| CA2361621A1 (en) * | 1999-01-27 | 2000-08-03 | Richard Jove | Inhibition of stat3 signal transduction for human cancer therapy |
| EP1551392A4 (en) * | 2002-09-17 | 2006-09-20 | Arqule Inc | NEW LAPACHO COMPOUNDS AND APPLICATION METHOD THEREFOR |
| TWI335913B (en) * | 2002-11-15 | 2011-01-11 | Vertex Pharma | Diaminotriazoles useful as inhibitors of protein kinases |
| US8623405B2 (en) * | 2005-01-28 | 2014-01-07 | Takeda Pharmaceutical Company Limited | Finely divided composition containing poorly water soluble substance |
| JP2006290871A (ja) * | 2005-03-16 | 2006-10-26 | Taheebo Japan Kk | 抗癌性を示す化合物およびその中間体ならびにそれらの製造方法 |
| TW200803854A (en) * | 2005-09-30 | 2008-01-16 | Smithkline Beecham Corp | Pharmaceutical compositions |
| EP1860126A1 (en) * | 2006-05-26 | 2007-11-28 | INEOS Manufacturing Belgium NV | Polyolefin powder |
| SI2200431T1 (sl) * | 2007-09-10 | 2016-10-28 | Boston Biomedical, Inc. | Sestave in metode za zdravljenje raka |
| CN101878218B (zh) * | 2008-07-08 | 2013-01-02 | 浙江贝达药业有限公司 | 埃克替尼盐酸盐及其制备方法、晶型、药物组合物和用途 |
| BR112012023661A2 (pt) * | 2010-03-19 | 2020-11-24 | Boston Biomedical, Inc. | novos compostos e novas composições direcionadas a células-tronco cancerosas |
| CN106860443A (zh) * | 2010-03-19 | 2017-06-20 | 北京强新生物科技有限公司 | 靶向癌症干细胞的新的化合物和组合物 |
| AU2011227023B2 (en) * | 2010-03-19 | 2015-05-28 | Boston Biomedical, Inc. | Novel methods for targeting cancer stem cells |
-
2011
- 2011-03-21 CN CN201710134235.3A patent/CN106860443A/zh active Pending
- 2011-03-21 CA CA2993363A patent/CA2993363A1/en not_active Abandoned
- 2011-03-21 SG SG10201502079VA patent/SG10201502079VA/en unknown
- 2011-03-21 EP EP16182813.2A patent/EP3108750B1/en active Active
- 2011-03-21 NZ NZ712826A patent/NZ712826A/en unknown
- 2011-03-21 PT PT117571356T patent/PT2547205T/pt unknown
- 2011-03-21 NZ NZ701237A patent/NZ701237A/en not_active IP Right Cessation
- 2011-03-21 CN CN201410101861.9A patent/CN104016951B/zh active Active
- 2011-03-21 CN CN201710613672.3A patent/CN107311969B/zh active Active
- 2011-03-21 CA CA2959931A patent/CA2959931A1/en not_active Abandoned
- 2011-03-21 RU RU2016123004A patent/RU2657750C1/ru active
- 2011-03-21 SG SG10201706265PA patent/SG10201706265PA/en unknown
- 2011-03-21 SG SG10201704745UA patent/SG10201704745UA/en unknown
- 2011-03-21 EP EP17196754.0A patent/EP3295796A1/en active Pending
- 2011-03-21 ES ES16182813.2T patent/ES2689928T3/es active Active
- 2011-03-21 CA CA2959951A patent/CA2959951A1/en not_active Abandoned
- 2011-03-21 DK DK16182813.2T patent/DK3108750T3/en active
- 2011-03-21 HU HUE11757135A patent/HUE066482T2/hu unknown
- 2011-03-21 RU RU2015142279A patent/RU2015142279A/ru not_active Application Discontinuation
-
2014
- 2014-03-03 JP JP2014040227A patent/JP2014098050A/ja not_active Withdrawn
- 2014-03-03 JP JP2014040226A patent/JP2014098049A/ja not_active Withdrawn
- 2014-03-03 JP JP2014040225A patent/JP5993390B2/ja not_active Expired - Fee Related
-
2015
- 2015-02-25 JP JP2015035285A patent/JP2015098489A/ja active Pending
- 2015-09-11 JP JP2015179115A patent/JP6246169B2/ja not_active Expired - Fee Related
-
2016
- 2016-09-30 JP JP2016194176A patent/JP2016222723A/ja not_active Withdrawn
-
2017
- 2017-10-13 JP JP2017199380A patent/JP2018002744A/ja not_active Withdrawn
-
2018
- 2018-04-20 JP JP2018081329A patent/JP2018115209A/ja not_active Withdrawn
-
2020
- 2020-01-31 JP JP2020014705A patent/JP2020063308A/ja not_active Withdrawn
- 2020-05-08 JP JP2020082479A patent/JP2020114888A/ja active Pending
-
2021
- 2021-12-06 JP JP2021197732A patent/JP2022020002A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014098050A5 (enExample) | ||
| ES2745471T3 (es) | Formulaciones orales de liberación inmediata para quinazolinonas sustituidas | |
| JP2014098048A5 (enExample) | ||
| CN103096895B (zh) | 烟酸模拟物及其使用的方法 | |
| RU2012144421A (ru) | Новые соединения и композиции для нацеливания на злокачественные стволовые клетки | |
| JP2019011369A (ja) | がんの処置に使用するための２−アセチルナフト［２，３−ｂ］フラン−４，９−ジオン | |
| KR20170087926A (ko) | 지방산 시스테아민 콘주게이트 및 자가포식의 활성제로서 이의 용도 | |
| JP2015503593A5 (enExample) | ||
| RU2012144420A (ru) | Новые способы направленного воздействия на раковые стволовые клетки | |
| WO2013130625A1 (en) | Phospho-ester derivatives and uses thereof | |
| EA028452B1 (ru) | Лечение рака молочной железы | |
| JP2016516772A (ja) | オキサシクロヘプタン及びオキサビシクロヘプテンの配合物 | |
| KR20190018486A (ko) | 암의 예방 및/또는 치료를 위한 화합물, 조성물 및 방법 | |
| WO2011084623A1 (en) | Method of sensitizing cancer cells to the cytotoxic effects of death receptor ligands in cancer treatment | |
| KR20140099492A (ko) | 삼환식 화합물, 이를 포함하는 조성물 및 그의 용도 | |
| JP2018002744A (ja) | がん幹細胞を標的とするための新規の方法 | |
| EP3458448A1 (en) | Methods of using fasn inhibitors | |
| RU2015140611A (ru) | Коньюгат бензофуранона и индола или азаиндола, его получение и применения | |
| CN113893240A (zh) | 包含15-hepe的组合物和其使用方法 | |
| CN101600426B (zh) | 用于治疗肠道疾病的异山梨醇单硝酸酯衍生物 | |
| EP3858836A1 (en) | Compound and use thereof | |
| WO2014183673A1 (zh) | 阿那格雷及其衍生物的抗肿瘤用途 | |
| RU2014125519A (ru) | Ацил-гидразоновые и оксадиазоловые соединения, фармацевтические композиции, содержащие их, и их применение | |
| CN1731991A (zh) | 丁二酸衍生物酯类化合物治疗痴呆症的用途 | |
| TWI449704B (zh) | 嗎啡喃衍生物之結晶、其製造方法、及使用其之醫藥組成物 |